GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...

Incyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

A new study highlights recent, but fluctuating, growth in global human antibiotic consumption, one of the main drivers of growing antimicrobial resistance (AMR).

Following US President-elect Donald Trump's announcement that Robert F Kennedy (RFK) Jr will be appointed as head of the ...

President-elect Trump’s decision to nominate Robert F. Kennedy Jr. for Health and Human Services (HHS) secretary will put ...

The upcoming clinical trial conferences will host talks on supply chain resilience, AI’s growing role and forging industry ...

UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...